Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ
1.98
-0.08 (-3.88%)
Delayed Data
Oct 23, 2026, 01:30 PM
Day's Range
1.902.05
52 wk Range
1.503.60
Financial Statements - ABOS - Acumen Pharmaceuticals, Inc.
Revenue
0
Net Income
-121.33M▼ 18.6%
EBITDA
-116.46M▼ 16.8%
Free Cash Flow
-115.62M▼ 34.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -123.83M | -114.01M | -61.13M | -45.23M | -19.58M | -7.91M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -726K | 1.43M | -1.44M | -11K | -81.10M | 586K |
| Pre Tax Income | -121.33M | -102.32M | -52.37M | -42.85M | -100.60M | -7.32M |
| Income Tax | - | - | - | - | - | - |
| Net Income | -121.33M | -102.32M | -52.37M | -42.85M | -100.60M | -7.32M |
| EPS Basic | -2 | -1.71 | -1.08 | -1.06 | -5.02 | -0.255656 |
| EPS Diluted | -2 | -1.71 | -1.08 | -1.06 | -5.02 | -0.255656 |
| Basic Shares Outstanding | 60.56M | 60.01M | 48.60M | 40.60M | 20.05M | 28.65M |
| Diluted Shares Outstanding | 60.56M | 60.01M | 48.60M | 40.60M | 20.05M | 28.65M |
| Ebit | -117.11M | -98.26M | -51.79M | -42.85M | -19.58M | -7.91M |
| Ebitda | -116.46M | -99.67M | -50.24M | -42.68M | 61.57M | -8.49M |
| Net Income Continuous Operations | -121.33M | -102.32M | -52.37M | -42.85M | -100.60M | -7.32M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | 586K |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
